Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Evaluation of Combination CLK/DYRK (Cirtuvivint) Inhibition With PARP Inhibition (Olaparib) in BRCA/HRD Platinum Resistant Ovarian Cancer

NCT06856499 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT06856499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06856499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Evaluation of Combination CLK/DYRK (Cirtuvivint) Inhibition With PARP Inhibition (Olaparib) in BRCA/HRD Platinum Resistant Ovarian Cancer
Lead sponsor
University of Colorado, Denver
Phase
Phase 1
Overall status
Recruiting
Start date
December 8, 2025
Completion date
September 1, 2030
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

endometrioid ovarian cancer, fallopian tube cancer, primary peritoneal cancer